Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEET URO 12: Niraparib maintenance versus best supportive care in advanced or metastatic urothelial cancer
2018-004147-24Phase 2Active
- Sponsor
- University of Turin, Department of Oncology
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Niraparib maintenance + best supportive care with Best supportive care alone (2 arms). Primary endpoint: Progression-free survival. Started Nov 2020; status: active.
02
Drugs
niraparib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2018-004147-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004147-24.